Article
#ESMO20: 'As good as any PD-1 out there': Regeneron flashes PD-(L)1 lung cancer data to rival Merck
Rating:
0.0
Views:
267
Likes:
1
Library:
1
Regeneron entered the PD-(L)1 game late, so they devised a two-pronged strategy to catch up with Big Pharma rivals: They would push it into cancers where PD-1s had yet been tested, and they would prove that it's as powerful in the big indications as any other on the market. They
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value